Form 6-K GLAXOSMITHKLINE PLC For: Feb 18
FORM 6-K/A
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
athe Securities Exchange Act of 1934
For period ending February 2015
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
Vesting of conditional share awards under the
GlaxoSmithKline Share Value Plan
This notification sets out the vesting of awards over Ordinary Shares and American Depositary Shares (ADS) in GlaxoSmithKline plc, made in 2012 under the GlaxoSmithKline Share Value Plan (SVP), which were conditional on continued employment with the GlaxoSmithKline group.
The restricted period for the 2012 SVP awards, which commenced on 22 August 2012, has now ended and the awards made have vested. The awards made to the connected person of a Person Discharging Managerial Responsibility (PDMR) vested on 17 February 2015 and details are given in the table below.
Name of
Director / PDMR
|
Name of Connected person
|
Number of Ordinary Shares vested
|
Number of ADS vested
|
Dr M Slaoui*
|
Mrs K Slaoui
|
2,300
|
* Denotes an Executive Director
The Company and the above individual were advised of this transaction on 18 February 2015.
The fair market value of an ADS of GlaxoSmithKline plc at the point of vesting on 17 February 2015 was US$47.71.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
V A Whyte
Company Secretary
18 February 2015
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: February 18, 2015
By: VICTORIA WHYTE
----------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GSK (GSK) call put ratio 12 calls to 1 put with focus on April weekly (26) 41 calls
- Purpose Investments Inc. Announces Updated April 2024 Distribution Rate and Record and Ex-Distribution dates for Purpose High Interest Savings Fund, Purpose US Cash Fund, Purpose Cash Management Fund,
- SBA Announces 2024 Growth Accelerator Fund Competition Stage One Winners, Up to $3 Million in Prizes Awarded
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!